About GH Research
GH Research is a publicly listed company based in Dublin (Ireland) founded in 2018 by Magnus C Halle and Theis Terwey. Therapeutics for mental disease management are developed using 5-MeO-DMT formulations. GH Research has raised $125 million across 1 funding round from investors including Citadel, RTW Investments and RA Capital. The company has 50 employees. Its chief executive, as recorded, is Theis Terwey. Its website ghres.com draws about 17 thousand monthly visits. GH Research offers products and services including GH001 and GH002. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric.
Company details
GH Research was founded in 2018 and is based in Dublin, Ireland. Focus is placed on the biotechnology sector, where treatments for mental disorders are developed. The pipeline includes GH001, an inhalable 5-MeO-DMT product intended for resistant depression and related conditions, and GH002, an injectable 5-MeO-DMT formulation for mental health applications. Operations center on advancing these candidates through clinical stages.
- Net Profit-$48.26 M (USD)-23.86as on Dec 31, 2025
- EBITDA-$60.34 M (USD)-20.85as on Dec 31, 2025
- Total Equity Funding$125M (USD)
in 1 rounds
- Latest Funding Round$125M (USD), Series B
Apr 2021
- InvestorsCitadel
& 10 more
- Employee Count50
Products & Services of GH Research
GH Research offers a comprehensive portfolio of products and services, including GH001 and GH002.
Pulmonary inhalation therapy for depression treatment
Intravenous administration for neurological disorders
Funding Insights of GH Research
GH Research has successfully raised a total of $125M through 1 strategic funding round. The most recent funding activity was a Series B round of $125 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $125M
- Total Rounds 1
- Last Round Series B — $125M
- First Round $125M
(Apr 2021)
- Investors Count 11
All 1 funding rounds of GH Research with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | $125M | Series B | – | RA Capital Management, RTW Investments |
11 investors in total: 11 institutional.
Investors in GH Research
GH Research has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Citadel, RTW Investments and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
VC & PE firm focused on healthcare sector | venrockcp.com | Palo Alto, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Provides financial investments to healthcare firms for health and well-being innovation. | 2015 | acutacapital.com | Belmont, United States | |
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
Provider of investment & fund management services | 2008 | verition.com | Greenwich, United States |
Investor details for GH Research
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GH Research
16 people are tracked at GH Research (4 in leadership, 9 in board & advisors, 3 in team); the tracked headcount is 50.
| Name | Role | Group |
|---|---|---|
Magnus C Halle | Co-Founder & Managing Director | Leadership |
Theis Terwey | Co-Founder & CEO | Leadership |
Julie Ryan | VP, Finance | Leadership |
PD Dr. med. Theis Terwey | Co-founder | Leadership |
Florian Schönharting | Co-Founder & Chairman | Board & advisors |
Malek Bajbouj | Scientific Advisor | Board & advisors |
Michael Thase | Scientific Advisor | Board & advisors |
Michael Bauer | Scientific Advisor | Board & advisors |
Eduard Vieta | Scientific Advisor | Board & advisors |
Madhukar Trivedi | Scientific Advisor | Board & advisors |
Mark Zimmerman | Scientific Advisor | Board & advisors |
Johannes Ramaekers | Scientific Advisor | Board & advisors |
Michael Forer | Director | Board & advisors |
Jack McGinley | Financial Accountant | Team |
Claire Monks | Accounts Payable Specialist | Team |
Leana van Vuuren | Finance Manager | Team |
Complete people profiles for GH Research
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GH Research
GH Research is a publicly listed company on the NASDAQ with ticker symbol GHRS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Jun 2021
- Listed onNASDAQ: GHRS
- Listed entityGH Research PLC
- Exchange sectorHealth technology
- ISINIE000GID8VI0
- Share price$18.85 (-5.84% on the day) · 2026-10-13
- Market capitalisation$1.29B
- EPS (diluted, trailing year)$-0.99
- Volume (last session)425,518
Financials of GH Research
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$48.3M | -$60.3M | |
| 2024 | -$39.0M | -$49.9M | |
| 2023 | -$35.6M | -$40.9M | |
| 2022 | -$22.5M | -$30.5M | |
| 2021 | -$9.2M | -$15.1M |
Detailed financial statements for GH Research
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of GH Research
3 dated milestones of GH Research across 3 years, from founding to its latest funding, stage changes and deals.
- Founded GH Research is founded.
- Funding First funding round of $125.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of GH Research
The website of GH Research (ghres.com) receives about 17.1K visits a month.
- Monthly visits17.1K
▲ 318.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gh Research
Complete news archive for GH Research
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GH Research
GH Research was founded in 2018 and raised its 1st funding round 3 years after it was founded.
GH Research is headquartered in Dublin, Ireland.
Theis Terwey is the CEO of GH Research, as recorded in our data. They have also founded this company.
GH Research is a funded company, having raised a total of $125M across 1 funding round to date. The company's 1st funding round was a Series B of $125M, raised on Apr 2021.
GH Research has 50 employees.
GH Research was founded in 2018 and is based in Dublin, Ireland. Focus is placed on the biotechnology sector, where treatments for mental disorders are developed. The pipeline includes GH001, an inhalable 5-MeO-DMT product intended for resistant depression and related conditions, and GH002, an injectable 5-MeO-DMT formulation for mental health applications. Operations center on advancing these candidates through clinical stages.
GH Research offers GH001 and GH002.
Yes, GH Research is publicly traded on NASDAQ under the ticker symbol GHRS.
GH Research has 11 investors. Key investors include Citadel, RTW Investments, RA Capital, Verition Fund Management, and BVF Partners.